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alreticulin is a Ca
 
2
 
 
 
-binding chaperone in the en-
doplasmic reticulum (ER), and calreticulin gene
knockout is embryonic lethal. Here, we used cal-
reticulin-deﬁcient mouse embryonic ﬁbroblasts to examine
 
the function of calreticulin as a regulator of Ca
 
2
 
 
 
 homeostasis.
In cells without calreticulin, the ER has a lower capacity for
Ca
 
2
 
 
 
 storage, although the free ER luminal Ca
 
2
 
 
 
 concentration
is unchanged. Calreticulin-deﬁcient cells show inhibited Ca
 
2
 
 
 
release in response to bradykinin, yet they release Ca
 
2
 
 
 
 upon
direct activation with the inositol 1,4,5-trisphosphate (InsP
 
3
 
).
These cells fail to produce a measurable level of InsP
 
3
 
 upon
stimulation with bradykinin, likely because the binding of
C
 
bradykinin to its cell surface receptor is impaired. Bradyki-
nin binding and bradykinin-induced Ca
 
2
 
 
 
 release are both
restored by expression of full-length calreticulin and the
 
N 
 
  
 
P domain of the protein. Expression of the P 
 
  
 
C do-
main of calreticulin does not affect bradykinin-induced
Ca
 
2
 
 
 
 release but restores the ER Ca
 
2
 
 
 
 storage capacity. Our
results indicate that calreticulin may play a role in folding
of the bradykinin receptor, which affects its ability to ini-
tiate InsP
 
3
 
-dependent Ca
 
2
 
 
 
 release in calreticulin-deﬁcient
cells. We concluded that the C domain of calreticulin plays
a role in Ca
 
2
 
 
 
 storage and that the N domain may partici-
pate in its chaperone functions.
 
Introduction
 
Calreticulin is a Ca
 
2
 
 
 
-binding chaperone found in the lumen
of the endoplasmic reticulum (ER)* (Michalak et al., 1999).
The protein binds monoglucosylated oligosaccharides (Ber-
geron et al., 1994; Helenius et al., 1997) and misfolded pro-
teins (Saito et al., 1999), and it is believed to play a critical
role in quality control processes during protein synthesis and
folding (Helenius et al., 1997). Several studies indicate that
increased expression of calreticulin increases the Ca
 
2
 
 
 
 storage
capacity of the ER (Michalak et al., 1999). It also appears to
modulate store-operated Ca
 
2
 
 
 
 influx (Bastianutto et al., 1995;
Mery et al., 1996; Fasolato et al., 1998; Xu et al., 2000) and
to alter Ca
 
2
 
 
 
 transport by the sarcoplasmic/endoplasmic retic-
ulum Ca
 
2
 
 
 
-ATPase, SERCA2b (John et al., 1998). Evidence
now indicates that Ca
 
2
 
 
 
-binding chaperones in the lumen of
the ER affect luminal Ca
 
2
 
 
 
 concentrations ([Ca
 
2
 
 
 
]
 
ER
 
) (Mel-
dolesi and Pozzan, 1998) and that agonist-induced changes in
[Ca
 
2
 
 
 
]
 
ER
 
 affect ER function (Corbett and Michalak, 2000).
 
Mice homozygous for calreticulin gene disruption (
 
crt
 
 
 
/
 
 
 
)
showed a marked decrease in ventricular wall thickness and in
deep intertrabecular recesses in the ventricular walls, indicating
that calreticulin is essential for proper cardiac development
(Mesaeli et al., 1999; Rauch et al., 2000). Agonist-induced
Ca
 
2
 
  
 
release via the inositol 1,4,5-trisphosphate (InsP
 
3
 
)
pathway is inhibited in 
 
crt
 
 
 
/
 
 
 
 cells as is Ca
 
2
 
 
 
-dependent trans-
location of nuclear factor in activated T cells (Mesaeli et al.,
1999). These results indicate that calreticulin, in addition to
being a chaperone, plays a critical role in Ca
 
2
 
 
 
 homeostasis.
In these studies, we used calreticulin-deficient mouse em-
bryonic fibroblasts to examine the in vivo function of calre-
ticulin as a regulator of Ca
 
2
 
 
 
 homeostasis. In cells without
calreticulin, the ER has a lower capacity for storage of Ca
 
2
 
 
 
,
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*Abbreviations used in this paper: [Ca
 
2
 
 
 
]
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, cytoplasmic Ca
 
2
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2
 
 
 
]
 
ER
 
, ER luminal Ca
 
2
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lum; InsP
 
3
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3
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although the free [Ca
 
2
 
 
 
]
 
ER 
 
as measured by an ER-targeted
“cameleon” reporter is not changed. Bradykinin-induced
Ca
 
2
 
 
 
 release is inhibited in calreticulin-deficient cells, yet
they release Ca
 
2
 
 
 
 in response to InsP
 
3
 
. Apparently, 
 
crt
 
 
 
/
 
 
 
cells fail to produce measurable levels of InsP
 
3
 
 in response to
bradykinin, likely because of impaired binding of bradyki-
nin to its cell surface receptor. Our findings suggest that in
calreticulin-deficient cells altered folding of the bradykinin
receptor adversely affects its ability to initiate InsP
 
3
 
-depen-
dent Ca
 
2
 
 
 
 release and that different domains of calreticulin
may play distinct functions in the lumen of ER.
 
Results
 
Calreticulin-deficient mouse embryonic fibroblasts
 
To determine the effects of calreticulin deficiency on ER
function, we isolated mouse embryonic fibroblasts from 
 
crt
 
 
 
/
 
 
 
and wild-type embryos. These cell lines were designated
 
K41 for wild-type mouse embryonic fibroblasts and K42 for
calreticulin-deficient mouse embryonic fibroblasts. Some of
the calreticulin-deficient cells (K42) were also transfected
with a calreticulin expression vector and were designated
K42CRT. As expected, Western blot analysis revealed that
the K41 and K42CRT cells contained immunoreactive cal-
reticulin (Fig. 1 A, lanes 1 and 3), whereas the K42 
 
crt
 
 
 
/
 
 
 
cells did not (Fig. 1 A, lane 2). The morphological appear-
ance of the wild-type (K41) and calreticulin-deficient (K42)
cells was indistinguishable and typical of fibroblasts (Fig. 1
B). The cell lines all attached firmly to plastic, and we de-
tected no differences in the kinetics of their long-term (14 d)
growth (unpublished data). Fig. 1 C shows that K41 and
K42CRT cells both expressed calreticulin and that the pro-
tein was localized to an ER-like network. As expected, there
was no expression of calreticulin in K42 cells. Morphologi-
cally, at a light microscope level the ER appeared intact in all
cell lines as judged by staining with antibodies against pro-
Figure 1. Calreticulin-deficient mouse 
embryonic fibroblasts. (A) Western blot 
analysis of calreticulin in mouse embry-
onic fibroblasts. Wild-type (K41) and 
calreticulin-deficient (K42) cells were 
lysed, and proteins were separated by 
SDS-PAGE, transferred to nitrocellulose 
membrane, and probed with anticalre-
ticulin antibodies. Lane 1, wild-type K41 
mouse embryonic fibroblasts; lane 2, 
calreticulin-deficient (crt
 / ) K42 mouse 
embryonic fibroblasts; lane 3, calreticu-
lin-deficient fibroblasts transfected with 
expression vector containing cDNA en-
coding calreticulin (K42CRT). (B) Phase–
contrast analysis of K41 and K42 cells. 
(C) Immunostaining of K41, K42, and 
K42CRT cells with anti-CRT, anti-Grp94, 
and anti-PDI antibodies. 
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tein disulfide isomerase (PDI) and Grp94 (Fig. 1 C). We ob-
served typical nuclear morphology in all of the cell lines and
the actin cytoskeleton visualized by labeling with fluorescent
phalloidin also appeared normal (unpublished data).
 
[Ca
 
2
 
 
 
]
 
ER
 
 capacity in calreticulin-deficient cells
 
The overexpression of calreticulin leads to an increased total
Ca
 
2
 
 
 
 content in the lumen of the ER (Michalak et al.,
 
1999). This indicates that calreticulin somehow alters the
Ca
 
2
 
 
 
 storage capacity of the ER. Therefore, we used 
 
45
 
Ca
 
2
 
 
 
to estimate the Ca
 
2
 
 
 
 content of the ER in calreticulin-defi-
cient cells (Mery et al., 1996). Wild-type cells (K41) con-
tained 44 
 
 
 
 3 pmol of Ca
 
2
 
 
 
/10
 
6
 
 cells, whereas the calreticu-
lin-deficient cells (K42) contained 24 
 
 
 
 4 pmol of Ca
 
2
 
 
 
/10
 
6
 
cells. Thus, the absence of calreticulin resulted in a 
 
 
 
1.8-
fold reduction in cellular Ca
 
2
 
 
 
 content.
Next, we used thapsigargin, an inhibitor of the Ca
 
2
 
 
 
-ATP-
ase, to measure the amount of Ca
 
2
 
 
 
 associated with rapidly
exchangeable stores. To measure the residual amounts of
Ca
 
2
 
 
 
 contained within thapsigargin-insensitive stores, we
added the Ca
2  ionophore ionomycin. In these experiments,
cells were equilibrium loaded with 
45Ca
2  and then resus-
pended in a nonradioactive Ca
2 -free medium (Mery et al.,
1996). Fig. 2 shows that in response to thapsigargin the
wild-type cells (K41) released almost twice as much 
45Ca
2 
as the calreticulin-deficient cells (K42). When the remaining
45Ca
2  was released with ionomycin, the amount released
from K41 cells was greater than from K42 cells (Fig. 2 A).
Fig. 2 A also shows that there was an increase in Ca
2  release
in the presence of ionomycin compared with thapsigargin
alone. This is likely due to ionomycin-dependent Ca
2  re-
lease from intracellular compartments other than ER includ-
ing mitochondria. To confirm that the absence of calreticu-
lin caused the decreased Ca
2  content of the K42 cells, some
K42 cells were stably transfected with a calreticulin expres-
sion vector, creating the K42CRT cell line (Fig. 1). Fig. 2 A
shows that the Ca
2  content of thapsigargin-sensitive stores
was indistinguishable in K42CRT and wild-type (K41) cells.
We conclude that the absence of calreticulin in K42 cells
causes a significant decrease in the Ca
2  content of thapsi-
gargin-sensitive stores.
The C domain of calreticulin affects ER Ca
2  storage 
capacity in vivo
K42 (crt
 / ) cells provide us with an excellent tool for inves-
tigating the role of calreticulin’s different domains in deter-
mining ER Ca
2  storage capacity in vivo. Calreticulin binds
Ca
2  with high capacity to its COOH-terminal domain
(Michalak et al., 1999), but the effects of this binding have
not been documented in vivo. To investigate the effect of
calreticulin’s C domain on the Ca
2  storage capacity of
thapsigargin-sensitive stores, we transfected K42 (calreticu-
lin-deficient) cells with expression vectors encoding different
domains of the protein. cDNA encoding N   P and P   C
domain of calreticulin contained HA epitope for immuno-
logical detection of the recombinant proteins. Using anti-
HA tag antibodies, we showed that calreticulin-deficient
cells transfected with expression vectors encoding N   P or
P   C domain expressed similar levels of both recombinant
proteins (Fig. 2 B). Despite numerous attempts, we have
been unable to create a K42 (calreticulin-deficient) cell line
expressing the C domain of calreticulin alone. Attempts to
create other cell lines that overexpress the C domain of cal-
reticulin (HeLa, HEK293, CHO) have also failed. This is
probably because the C domain, when expressed alone, is
very unstable (Corbett et al., 2000). However, we can ex-
press the C domain of calreticulin when the central P do-
main is also included (Fig. 2 B, lane 3). Although the P do-
Figure 2. ER Ca
2  content in calreticulin-deficient cells. Calreticu-
lin-deficient cells (K42) were transfected with expression vectors 
encoding calreticulin or calreticulin domains followed by measure-
ment of a total cellular Ca
2 . (A) A total cellular Ca
2  content was 
determined using equilibrium incubation with 
45Ca
2  followed by 
addition of thapsigargin (estimates Ca
2  pool in thapsigargin-sensi-
tive Ca
2  stores) or ionomycin (estimates Ca
2  pool in thapsigargin-
insensitive Ca
2  stores) (Mery et al., 1996). Ca
2  content was mea-
sured in wild-type (K41), crt
 /  (K42), and K42 cells transfected with 
expression vectors encoding either calreticulin (K42CRT), the N   P 
domain of calreticulin (K42N P), or the P   C domain of the protein 
(K42P C). Data shown are means   SE (n   3). (B) Western blot 
analysis with anti-HA tag antibodies of K42 calreticulin-deficient 
cells expressing calreticulin domains. Lane 1, calreticulin-deficient 
cells (K42); lane 2, K42 cells transfected with expression vectors 
encoding the N   P domain of calreticulin (K42N P); lane 3, K42 
transfected with expression vector encoding the P   C domain of the 
protein (K42P C). Similar levels of both, the 38-kD N   P domain 
and the 36-kD P   C domain were expressed in transfected cells.964 The Journal of Cell Biology | Volume 154, 2001
main of calreticulin also binds Ca
2 , it binds only 1 mol/mol
of protein with high affinity (Michalak et al., 1999). Fig. 2 A
shows that expression of the P   C domain in calreticulin-
deficient K42 cells (K42P C) dramatically increased thapsi-
gargin-sensitive Ca
2  release compared with that seen in the
parental K42 cell line. This indicates that the P   C domain
of calreticulin modulates ER Ca
2  storage capacity. The rea-
son for unusually high ER Ca
2  in the P   C domain–
expressing cells is not clear at present. This may be due to an
increased Ca
2  capacity of the P   C domain in the ER lu-
men in the absence of the N domain of calreticulin.
Next, we created K42 (calreticulin-deficient) cell lines ex-
pressing the N    P domain of calreticulin (Fig. 2 A,
K42N P). We found no significant difference in Ca
2  stor-
age capacity in K42 and K42N P cells (Fig. 2 A), indicating
that neither the N domain nor the P domain of calreticulin
modulates thapsigargin-sensitive (ER) Ca
2  storage capacity.
Our results show that calreticulin via its C domain plays a
role in determining the Ca
2  storage capacity of the ER.
Free [Ca
2 ]ER in calreticulin-deficient cells
To determine the free [Ca
2 ]ER in calreticulin-deficient cells,
we transfected wild-type (K41) and calreticulin-deficient
(K42) mouse embryonic fibroblasts with the ER-targeted
cameleon YC4ER (Arnaudeau et al., 2001), a Ca
2  indicator,
which relies on fluorescent proteins and calmodulin
(Miyawaki et al., 1997). Fig. 3 A shows that the cameleon
was expressed in both cell types and was localized in a reticu-
lar pattern consistent with labeling of the ER. Fig. 3 B shows
that the free [Ca
2 ]ER did not differ significantly in the wild-
type cells (290   18  M Ca
2 ; mean   SE; n   18) and
calreticulin-deficient cells (288   20  M Ca
2 ; mean   SE;
n   22). In further studies, we used thapsigargin and iono-
mycin to completely deplete cellular Ca
2 stores. Under
these conditions, free [Ca
2 ]ER was reduced to 27   3  M
Ca
2  (mean   SE; n   15) in the wild-type cells and to
23   3  M Ca
2  (mean   SE) in the calreticulin-deficient
cells (Fig. 3 B). Our results indicate that although the total
Ca
2  content of the ER is significantly decreased in calre-
ticulin-deficient cells, the free [Ca
2 ]ER is unaltered both
when Ca
2  stores are full and when they are depleted.
Bradykinin-induced Ca
2  release in
calreticulin-deficient cells
We next performed experiments with the Ca
2 -sensitive flu-
orescent dye fura-2. Fig. 4 shows that in wild-type (K41)
cells, the resting free cytoplasmic Ca
2   concentration
([Ca
2 ]c) was  100   12 nM (mean   SD; n   3). In cal-
reticulin-deficient fibroblasts (K42), the resting free [Ca
2 ]c
was significantly increased (148   10 nM; mean   SD; n  
3). We also performed fura-2 analysis of [Ca
2 ]c in calreticu-
lin-deficient mouse embryonic fibroblasts, which had been
transfected with a calreticulin expression vector (K42CRT
cells). These cells, which express recombinant calreticulin,
had 108   13 nM (mean   SD; n   3) basal [Ca
2 ]c, indi-
cating that reintroduction of calreticulin to calreticulin-defi-
cient cells lowered the basal [Ca
2 ]c to the levels observed in
the wild-type (K41) cells (Fig. 4, A and B).
Next, we compared agonist-induced Ca
2  release in wild-
type (K41) and calreticulin-deficient fibroblasts (K42). In
preliminary experiments, we tested the effect of 100  M
carbachol, 1  M angiotensin II, 50 nM bombesin, 200 nM
bradykinin, and 25 ng PDGF/ml on Ca
2  release from the
wild-type cells. Among all these agonists, only bradykinin
resulted in Ca
2  release from the K41 cells, and so it was
used in our subsequent experiments. Furthermore, in full
agreement with our earlier report (Mesaeli et al., 1999)
bradykinin caused a rapid and transient increase in the cyto-
plasmic Ca
2  concentration in wild-type (K41) cells but not
in crt
 /  (K42) cells, indicating that Ca
2  release via InsP3-
dependent pathways is impaired in calreticulin-deficient
cells (Fig. 4, A and C). To show that calreticulin is involved
in this impairment, we investigated bradykinin-induced
Ca
2  release in K42CRT cells. Fig. 4, A and C, show that
the expression of calreticulin in K42 cells restored bradyki-
Figure 3. Free ER Ca
2  luminal concentration in K41 wild-type 
and K42 calreticulin-deficient cells. Cells were transiently trans-
fected with YC4ER and the ratio fluorescence calibrated to [Ca
2 ]ER 
using calibration curves obtained in situ (Arnaudeau et al., 2001). 
(A) Intracellular distribution of ER-targeted cameleon in wild-type 
(K41) and calreticulin-deficient (K42) cells. (A) Single wavelength 
cameleon fluorescence (emission at 535 nm) imaging of transfected 
cells revealing reticular pattern reminiscent of the ER. (B) Free 
[Ca
2 ]ER in K41 wild-type (white bars) and K42 calreticulin-deficient 
(gray bars) cells was measured with ER-targeted cameleon as 
described under Materials and methods. TG, thapsigargin; iono, 
ionomycin. Data are derived from 15–22 independent experiments.Calcium homeostasis in calreticulin-deficient cells | Nakamura et al. 965
nin-stimulated Ca
2  release. Importantly, the basal [Ca
2 ]c
was also decreased to levels observed in wild-type cells (Fig.
4, A and B).
In further experiments, we used a cameleon reporter to
make time-resolved measurements of free [Ca
2 ]ER in wild-
type and calreticulin-deficient cells. Bradykinin by itself had
little effects on [Ca
2 ]ER (unpublished data) but caused a
rapid [Ca
2 ]ER decrease when thapsigargin was included to
prevent ER refilling (Fig. 5 A). A pronounced Ca
2  release
was observed in wild-type cells, the [Ca
2 ]ER decreasing to
80   12  M within 150 s. (Fig. 5 C). Subsequent addition
of ionomycin had little effects on the kinetics of the
[Ca
2 ]ER response (Fig. 5 A), indicating the ER Ca
2  perme-
ability was maximally activated by the combination of
bradykinin and thapsigargin. In contrast, the addition of
bradykinin and thapsigargin to calreticulin-deficient cells
decreased [Ca
2 ]ER only to 114   18  M (Fig. 5 C), and
subsequent addition of ionomycin caused a further decrease
in [Ca
2 ]ER (Fig. 5 A). No differences were observed when
thapsigargin was added alone, the [Ca
2 ]ER decreasing with
similar kinetics and to similar levels in wild-type and calre-
ticulin-deficient cells (Fig. 5, B and C). The higher [Ca
2 ]ER
measured in calreticulin-deficient cells stimulated with
bradykinin and thapsigargin thus likely reflects the failure of
bradykinin to increase the ER Ca
2  permeability. These ob-
servations are in keeping with the fura-2 measurements pre-
sented in Fig. 4 and indicate that bradykinin-induced Ca
2 
release from the ER is impaired in the calreticulin-deficient
K42 cells.
SERCA2, the InsP3 receptor (InsP3R) and the bradykinin 
receptor in calreticulin-deficient cells
There are several potential explanations for the observation
that bradykinin-induced Ca
2  release is impaired in calreticu-
lin-deficient cells. For example, in crt
 /  (K42) cells there
could be changes in the expression and/or function of Ca
2 
transport proteins in the ER or in the bradykinin receptor in
the plasma membrane. To investigate these possibilities, we
first compared expression of SERCA2 and the InsP3R in
wild-type and calreticulin-deficient cells. Fig. 6 A shows that
the expression of SERCA2 was not altered in calreticulin-
deficient cells. Further, the level of mRNA for SERCA was the
same in wild-type (K41) and calreticulin-deficient (K42) cells
(unpublished data). We also used Western blot analysis (Fig.
6 B) and reverse transcriptase PCR (Table I) to compare ex-
pression of the three isoforms of the InsP3R (type 1, 2, and 3)
in K41 and K42 cells. All three isoforms of the InsP3R were
expressed in wild-type and crt
 /  cells (Fig. 6 B and Table I).
However, we found a 30–40% reduction in mRNA for the
InsP3R in calreticulin-deficient cells compared with the wild-
type cells (Table I). Western blot analysis of types 1, 2, and 3
of the InsP3R revealed that these cells contain all three types
of InsP3R at a ratio of 10:70:20 (Fig. 6). A significant de-
crease of  20% was found in the calreticulin-deficient K42
Figure 4. Bradykinin-induced Ca
2  release in calreticulin-
deficient cells. Cells were loaded with the fluorescent Ca
2  
indicator fura-2 and stimulated with 200 nM bradykinin. 
K41, wild-type mouse embryonic fibroblasts; K42, calreticu-
lin-deficient cells; K42CRT, K42 cells transfected with calre-
ticulin expression vector. (A) Represents typical traces show-
ing bradykinin (BK) stimulation of cells in a Ca
2 -free 
medium. Arrows indicate the time of addition of bradykinin. 
(B) Basal [Ca
2 ]c in wild-type (white bar), calreticulin-
deficient (black bar), and calreticulin-deficient cells trans-
fected with calreticulin expression vector (hatched bar). The 
absolute values of [Ca
2 ]c were: 100   12 nM (K41), 148   
10 nM (crt
 /  K42), and 95   8 nM (crt
 /    CRT, K42CRT). 
(C) Ca
2  released by bradykinin was significantly different in 
cell lines investigated. K41, wild-type mouse embryonic fi-
broblasts; K42, calreticulin-deficient cells; K42CRT, K42 
cells transfected with calreticulin expression vector. Data are 
mean   SE (n   3).
Table I. Quantitative analysis of mRNA encoding different isoforms of InsP3Rs in calreticulin-deficient K42 cells
K41 wild-type cells K42 calreticulin-deficient cells
%
InsP3R type 1 100 74.6   17.6
InsP3R type 2 100 58.0   17.8
InsP3R type 3 100 66.0   7.0
GAPDH 100 101.5   4.2
InsP3R 1/2/3 ratio (% of total level) 25.0/13.7/61.2 28.8/13.0/58.1
Reverse transcriptase PCR was carried out as described in Materials and methods. GAPDH was used as an internal standard. Data are mean   SD (n   3).966 The Journal of Cell Biology | Volume 154, 2001
cells for InsP3R type 1 (3.1   0.4 versus 2.6   0.4; n   4;
P   0.01) and for InsP3R type 3 (9.4   0.4 versus 7.5   0.6;
n   4; P   0.01). The relative level of InsP3R type 2 was ap-
proximately equal in both cell types (0.2   0.1; n   4).
Next, we compared expression of the bradykinin receptor
and its targeting to the plasma membrane in wild-type
(K41) and calreticulin-deficient (K42) cells. Fig. 7 A shows
that calreticulin-deficient cells had decreased level of brady-
kinin receptor protein. Quantitative analysis of Western
blots indicated that there was  50% less bradykinin recep-
tor in calreticulin-deficient cells compared with K41 wild-
type cells. These results indicate that calreticulin deficiency
had some effect on expression and/or turnover of the brady-
kinin receptor. Using confocal microscopy and antibodies
against the bradykinin receptor, we found that the receptor
was distributed in a “dotty” pattern across the cell surface in
K41, K42, and K42CRT cells (Fig. 7 B). We noticed no dif-
ference between the cell lines in distribution of the receptor
(Fig. 7 B). Cell surface localization of the receptor was fur-
ther confirmed by flow cytometry assay using antibradyki-
nin receptor antibodies. We observed no significant differ-
ence in the antibradykinin antibodies surface labeling of
K41 and K42 cells (Fig. 7 C), indicating the similar number
of immunoreactive receptor protein molecules was present
on cell surface. We concluded that in calreticulin-deficient
cells the bradykinin receptor was properly targeted to and lo-
calized in the plasma membrane.
InsP3-induced Ca
2  release and InsP3 synthesis in 
calreticulin-deficient cells
We have shown that expression of the InsP3R is reduced in
calreticulin-deficient (K42) cells, whereas expression of the
bradykinin receptor is not. Therefore, we wanted to deter-
mine whether the altered expression of the InsP3R was re-
sponsible for the impairment of bradykinin-induced Ca
2 
release in these cells. To test this hypothesis, we loaded wild-
type and calreticulin-deficient cells with fluo-3, and then we
added saponin to permeabilize the plasma membrane (Favre
et al., 1994). Subsequently, exogenous InsP3 was added to
Figure 5. Free [Ca
2 ]ER responses in bradykinin- and thapsigargin-
stimulated cells. Wild-type (K41) and calreticulin-deficient (K42) cells 
were transiently transfected with YC4ER expression vector. A and B 
show the time-course of spatially averaged [Ca
2 ]ER responses in cells 
stimulated with bradykinin and thapsigargin (BK   TG) or with thapsi-
gargin alone. The responses were measured in Ca
2 -free medium. 
When indicated, ionomycin (1  M) was added to maximally deplete 
ER Ca
2  stores. (C) [Ca
2 ]ER levels measured shortly after stimulation 
with bradykinin/thapsigargin or after full depletion of stores with 
thapsigargin. The absolute values were: 80   12  M (K41) and 114   
18  M (K42) for BK   TG, and 44   5  M (K41) 53   7  M (K42) for 
depletion with TG. BK, bradykinin; TG, thapsigargin; iono, ionomy-
cin. Data are mean   SE. n, number of experiments.
Figure 6. SERCA2 and InsP3R expression in calreticulin-deficient 
cells. (A) Wild-type (K41) and calreticulin-deficient (K42) mouse 
embryonic fibroblasts were lysed, and an increasing amount of pro-
tein (from 4 to 30  g) was separated in SDS-PAGE, transferred to 
nitrocellulose membrane, and probed with anti-SERCA2. (B) 
Microsomal vesicles were isolated from wild-type and calreticulin-
deficient cells followed by protein separation in SDS-PAGE. InsP3R 
type 1 (InsP3R1), InsP3R type 2 (InsP3R2), and InsP3R type 3 
(InsP3R3) proteins were identified by Western blot analysis. Lane 1, 
K41 cells; lane 2, K42 cells; lane 3, RBL-2H3 control cells. The 
lower molecular mass protein band in the InsP3R2 panel is an 
immunoreactive protein not related to InsP3R2, and it was not 
included in quantitative analysis. 50  g protein/lane was loaded 
except for the InsP3R2 samples (100  g protein/lane). The position 
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the digitonin-permeabilized cells, and Ca
2  release from the
ER was monitored by changes in fluo-3 fluorescence. Fig. 8
shows that InsP3-induced Ca
2  release from the ER was in-
distinguishable in the wild-type (K41) and calreticulin-defi-
cient (K42) cells, indicating that there is no difference in
function of the InsP3Rs in the different cell types.
Since InsP3-induced Ca
2  release in permeabilized crt
 / 
cells is normal, the impaired bradykinin-induced Ca
2  re-
lease in intact cells could result from a deficiency in InsP3
synthesis. To investigate this possibility, we incubated wild-
type and calreticulin-deficient cells with 200 nM bradykinin
and then measured InsP3 levels. Fig. 9 A shows that the in-
cubation with bradykinin resulted in significant synthesis of
InsP3 in the K41 cells. In contrast, when calreticulin-defi-
cient K42 cells were treated with bradykinin there was no
detectable synthesis of InsP3 (Fig. 9 A). We conclude that
impairment of bradykinin-induced Ca
2  release in crt
 / 
K42 cells likely results from a failure to synthesize InsP3.
Figure 7. Expression of bradykinin receptor in calreticulin-deficient cells. Mouse embryonic fibroblasts were harvested, lysed, and proteins 
were separated in SDS-PAGE, transferred to nitrocellulose membrane, and probed with antibradykinin receptor antibodies (A). The positions 
of molecular markers are indicated. The open arrowhead indicates the position of bradykinin receptor. (B) Localization of bradykinin receptor 
in wild-type (K41), calreticulin-deficient cells (K42), and calreticulin-deficient cells transfected with calreticulin expression vector (K42CRT). 
K42 mock-transfected control cells are also shown. In all cell lines, bradykinin receptor localizes to cell surface. (C) Bradykinin receptor 
expression on cell surface. Flow cytometry analysis of mouse embryonic fibroblasts was carried out with antibradykinin receptor antibodies. 
Results are presented as the relative mean fluorescence intensity after subtracting fluorescent values for the secondary antibodies alone. 
Results shown are representative of five experiments. K41, wild type cells; K42, calreticulin-deficient cells; BK, bradykinin receptor.968 The Journal of Cell Biology | Volume 154, 2001
Bradykinin binding in calreticulin-deficient cells
Our results indicate that bradykinin-dependent signaling is
impaired in calreticulin-deficient cells and that this results
from impaired InsP3 synthesis. Therefore, we measured
bradykinin binding to crt
 /  K42 cells. Fig. 9 B shows that
binding of [
3H]bradykinin to wild-type K41 cells was satura-
ble with a Bmax of  2.5   0.3 pmol/mg of total cell protein
(n   3). Scatchard analysis of the specific binding data gave
an apparent dissociation constant (Kd) of 230   20 pM.
These values are in agreement with previously reported Kd and
Bmax values for bradykinin receptors (Marceau et al., 1998). In
contrast, the binding of bradykinin to calreticulin-deficient
cells was significantly reduced (Bmax   0.5   0.01 pmol/mg
of protein; n   3) (Fig. 9 B), which would explain why these
cells show impairment of bradykinin-induced Ca
2  release
(Fig. 4). K42CRT cells, which express calreticulin and exhibit
normal bradykinin-induced Ca
2  release (Fig. 4), showed
bradykinin binding comparable to that seen in wild-type cells
(Bmax 2.7   0.3 pmol/mg of total cell protein; n   3; Kd of
225   25 pM) (Fig. 9 B). This was despite of a slightly lower
level of expression of the bradykinin receptor in K42CRT
cells (Fig. 7 A). We concluded that bradykinin binding to its
receptor is inhibited in calreticulin-deficient cells.
N   P domain of calreticulin restores
bradykinin-induced Ca
2  release from K42 cells
The data presented in Figs. 4 and 9 indicate that the impair-
ment of bradykinin-induced Ca
2  release in calreticulin-defi-
cient cells results from the failure of bradykinin to bind to
its receptor. This indicates that the bradykinin receptor may
be misfolded and therefore unable to bind bradykinin. In
preliminary experiments, we showed that calreticulin and
bradykinin receptor form complexes, which can be immu-
noprecipitated (unpublished data), indicating that calreticu-
lin may play a role in folding of the bradykinin receptor.
This presented us with a unique opportunity to investigate
the role of calreticulin’s different domains in its function as a
chaperone. We used bradykinin-induced changes in [Ca
2 ]c
as a measure of the function of the bradykinin receptor.
Cells were loaded with fura-2, stimulated with 200 nM
bradykinin, and changes in [Ca
2 ]c were monitored. As
shown in Fig. 10, in K42 crt
 /  cells expressing calreticulin
(K42CRT), bradykinin-induced Ca
2  release was restored to
the levels seen in wild-type cells. This indicates that full-
length calreticulin is required for normal ligand binding to
the receptor. Bradykinin-induced Ca
2  release was also rees-
tablished in K42 cells after transfection with the N   P do-
main of calreticulin (Fig. 10 B, K42N P). However, it was
not reestablished in cells expressing the P   C domain of
the protein (Fig. 10 B, K42P C). This indicates that the N
and P domain of calreticulin may play a role in peptide
binding and/or folding of the bradykinin receptor in mouse
embryonic fibroblasts.
Figure 8. Ca
2  release in saponin-permeabilized calreticulin-defi-
cient cells. Wild-type (K41) and calreticulin-deficient (K42) cells 
were loaded with a fluorescent Ca
2  indicator fluo-3 and permeabi-
lized with saponin. (A) InsP3 (10  M) was added at the time indi-
cated in the figure. (B) Basal [Ca
2 ]c in InsP3 incubated wild-type 
(white bar) and calreticulin-deficient (black bar). Data are means   
SD (n   3).
Figure 9. InsP3 production and [
3H]bradykinin binding in calreticu-
lin-deficient cells. (A) InsP3 synthesis was measured in wild-type (K41) 
and calreticulin-deficient (K42) cells incubated in the absence ( ) or 
presence ( ) of bradykinin as described in Materials and methods. 
Data are means   SD (n   3). (B) [
3H]bradykinin binding to wild-type 
(K41), calreticulin-deficient (K42), and calreticulin-deficient cells trans-
fected with calreticulin expression vector (K42CRT).Calcium homeostasis in calreticulin-deficient cells | Nakamura et al. 969
Discussion
In this study, we took advantage of a new calreticulin-defi-
cient cell line, which enabled us to address some of the many
outstanding questions regarding the function of calreticulin
and its distinct structural domains in the lumen of the ER.
We found that calreticulin-deficient cells have impaired
bradykinin-induced Ca
2  release, which results from a dys-
functional bradykinin receptor. The dysfunction probably
arises because the receptor is incorrectly folded and as a result
is unable to bind its ligand. Since the receptor cannot bind
the ligand, it fails to initiate the signal transduction cascade,
which normally leads to production of InsP3 and Ca
2  re-
lease from the ER via the InsP3R. These are the first studies
in which the function of calreticulin and of its distinct do-
mains have been tested against a calreticulin-deficient back-
ground. In these studies, we show that the C domain of cal-
reticulin plays a critical role in determining the Ca
2  storage
capacity of the ER and that the N   P domain but not the C
domain may play a role in the protein’s chaperone function.
This study shows that distinct regions (domains) of calreticu-
lin perform specialized functions in the ER lumen.
We have shown here that calreticulin plays an important
role in determining the Ca
2  storage capacity of the ER. This
fits with previous work, which has indicated that overexpres-
sion of calreticulin increases the Ca
2  capacity of InsP3-sensi-
tive Ca
2  stores (Bastianutto et al., 1995; Mery et al., 1996;
Fasolato et al., 1998; Xu et al., 2000). Specifically, we found
that there is a significant decrease in the Ca
2  storage capac-
ity of the ER in calreticulin-deficient mouse embryonic fi-
broblasts. This finding is in disagreement with the results of
other work in which calreticulin-deficient embryonic stem
cells were used (Coppolino et al., 1997). The cause of this
discrepancy is not clear, but it may result from the relatively
harsh conditions required for the selection of calreticulin-
deficient embryonic stem cells. Importantly, we found that
expression of either full-length calreticulin or its P   C do-
main in calreticulin-deficient fibroblasts restored the Ca
2 
capacity of the ER to normal levels. This indicates that the
P   C domains of calreticulin somehow help to determine
the Ca
2  storage capacity in the lumen of the ER. This most
likely occurs through the C domain of calreticulin, which
binds Ca
2  with high capacity (Michalak et al., 1999), but at
this stage a contribution by the P domain cannot be ruled
out because we have been unable to express the C domain of
calreticulin alone. Despite this, it is unlikely that the P do-
main has a role because expression of the N   P domain of
calreticulin does not affect the Ca
2  storage capacity of the
ER. For many years, it has been hypothesized that the C do-
main of calreticulin plays a role in determining the Ca
2 
storage capacity of the ER. These studies provide the first di-
rect evidence that this is indeed the case. Interestingly, al-
though calreticulin-deficiency has a profound effect on the
Ca
2  storage capacity of the ER it does not appear to affect
the free [Ca
2 ]ER as determined using cameleon techniques.
There are many obvious questions posed by the finding
that calreticulin affects the Ca
2  storage capacity of the ER.
For example, what are the physiological consequences of
modulating the Ca
2  storage capacity of the ER? It has al-
ready been suggested that changes in Ca
2  concentration in
the lumen of the ER may profoundly affect store-operated
Ca
2  influx (Fasolato et al., 1998). These kinds of changes
may also be involved in regulation of Ca
2  transport (John
et al., 1998), protein–protein interactions, and chaperone
function in the ER (Corbett and Michalak, 2000). Further,
recent reports indicate that the Ca
2  storage capacity of the
ER may play a role in determining cell sensitivity to apopto-
sis. For example, cells that overexpress Bcl-2 have a lower
Ca
2  in the lumen of the ER and are more resistant to apop-
tosis (Foyouzi-Youseffi et al., 2000; Pinton et al., 2000,
2001). In addition, calreticulin knockout cells, which have
reduced intraluminal Ca
2  concentrations, are also resistant
to apoptosis (Nakamura et al., 2000).
The nuclear export of the glucocorticoid receptor is inhib-
ited in calreticulin-deficient cells (Holaska et al., 2001). Cal-
reticulin may play a role in this directly or alternatively, and
these effects might be exerted through calreticulin’s role in
determining the Ca
2  storage capacity of the ER (and the
nuclear envelope). It seems that many of the diverse func-
tions proposed for calreticulin (Michalak et al., 1999) might
be explained by its effects on the ER Ca
2  storage capacity as
described here and by others (Bastianutto et al., 1995; Mery
et al., 1996; Fasolato et al., 1998; Xu et al., 2000).
Bradykinin-dependent Ca
2  signaling is impaired in cal-
reticulin-deficient cells (Mesaeli et al., 1999). At least partly,
this may explain why calreticulin deficiency is lethal. The
Ca
2  responses to bradykinin are also diminished as a result
of antisense oligodeoxynucleotide downregulation of calre-
ticulin expression (Liu et al., 1994). Normally bradykinin
binds to a cell surface receptor, and this leads to the activation
of PLC followed by the synthesis of InsP3 and the release of
Ca
2  from ER stores via the InsP3R (Hashii et al., 1993).
Since calreticulin is resident in the lumen of the ER, we
thought that the impairment of bradykinin-induced Ca
2  re-
lease in calreticulin-deficient cells might result from a direct
effect on InsP3R function. However, in this study we have
shown that calreticulin-deficient cells exhibit normal InsP3-
Figure 10. Role of the N   P domain of calreticulin in bradykinin-
induced Ca
2  release. Cells were loaded with the fluorescent Ca
2  
indicator fura-2 and stimulated with 200 nM bradykinin. A shows a 
basal [Ca
2 ]c, and B shows the amount of Ca
2  released by 200 nM 
bradykinin. K42, calreticulin-deficient cells; K42CRT, K42 cells 
transfected with calreticulin expression vector; K42N P, K42 cells 
transfected with N   P domain expression vector; K42P C, K42 
cells transfected with P   C domain expression vector. Data are 
means   SD (n   3).970 The Journal of Cell Biology | Volume 154, 2001
induced Ca
2  release but fail to produce InsP3 in response to
bradykinin. Although the calreticulin-deficient cells have
somewhat lower levels of the InsP3R, its function is appar-
ently unaffected. This indicates that cells can tolerate some
change in the expression of InsP3R without compromising
the ER’s ability to release Ca
2 . It is not clear why expression
of the InsP3R is decreased in calreticulin-deficient cells, but
Ca
2  and calcineurin may play a role. Calcineurin affects ex-
pression of the InsP3R at the transcriptional level (Genazzani
et al., 1999) and calcineurin-dependent transcriptional pro-
cesses are impaired in calreticulin-deficient cells.
Although the level of the bradykinin receptor is reduced
in crt
 /  cells, its targeting to the cell surface is unchanged,
indicating that the absence of calreticulin does not affect its
intracellular trafficking. Decreased expression of the brady-
kinin receptor may be due to increased degradation of the
receptor in calreticulin-deficient cells. Our results indicate
that calreticulin-deficient cells do not show bradykinin-
induced Ca
2  release because the bradykinin receptor is un-
able to bind its ligand. If the bradykinin cannot bind, the re-
ceptor is unable to stimulate phospholipase C activity and
synthesis of InsP3. Bradykinin-induced Ca
2  release can be
rescued in crt
 /  cells by reintroduction of full-length cal-
reticulin. Importantly, the N   P domain of calreticulin is
involved in this restoration, whereas the P   C domain is
not. We conclude that the N domain of calreticulin is some-
how essential for enabling interaction between the bradyki-
nin receptor and its ligand, most likely through assisting in
proper folding of the receptor’s ligand-binding domain. Al-
though we do not have direct evidence for this, it is conceiv-
able that the N domain may directly interact with bradyki-
nin receptor or it may recruit other chaperones necessary for
the receptor folding and/or posttranslational modification.
For example, the N domain interacts in vitro with ERp57
(Corbett et al., 1999), and this may be critical for proper
folding of the ligand binding of the receptor. At present, the
chaperone function of the P domain is not clear. This study
indicates that either the P domain plays less important chap-
erone role, or most likely its chaperone function requires the
presence of the N domain. However, this is the first evi-
dence that the chaperone function of calreticulin may be
also contained in the N domain of the protein.
It is widely thought that the central P domain of calreticu-
lin can act as a chaperone for glycosylated proteins because
of its amino acid sequence similarities to calnexin and its lec-
tin-like activity. However, a series of in vitro experiments in-
dicate that calreticulin may also function as a molecular
chaperone for nonglycosylated proteins (Saito et al., 1999).
Both ATP and Zn
2  enhance calreticulin’s ability to com-
plex with unfolded nonglycosylated substrates in vitro (Saito
et al., 1999). This likely occurs because of the dramatic con-
formational change, which occurs in calreticulin in the pres-
ence of Zn
2  (Khanna et al., 1986). Calreticulin binds Zn
2 
at its N domain (Michalak et al., 1999). The amino acid se-
quence of the N domain is extremely conserved among all
calreticulins and is also unique to calreticulin (Michalak et
al., 1999). This observation supports the suggestion that the
N domain of calreticulin has a highly specific function,
which may include the folding of specific substrates. The
bradykinin receptor may be such a substrate. Calreticulin
and calnexin both interact with monoglucosylated carbohy-
drates and therefore share many glycosylated substrates.
However, each one also interacts with a significantly differ-
ent spectrum of glycoproteins and proteins (Danilczyk et al.,
2000). The N domain of calreticulin may assist in recogni-
tion of calreticulin-specific substrates such as the bradykinin
receptor (this study). Notably, in support of this suggestion
bradykinin-dependent Ca
2  release is not altered in cal-
nexin-deficient cells (unpublished data).
In summary, we report here that calreticulin plays an im-
portant role in Ca
2  homeostasis in vivo. We show that the
C domain of calreticulin is involved in determining the
Ca
2  storage capacity of the ER and that the N   P domain
may play a role as a chaperone. It is clear that the chaperone
functions of calreticulin are tightly linked with its role in
Ca
2  homeostasis, and in this work specifically it appears
that improper binding of bradykinin to the receptor and/or
improper folding of the bradykinin receptor affect its ability
to induce Ca
2  release from ER Ca
2  stores. These studies
indicate that distinct regions (domains) of calreticulin per-
form specialized functions in the ER lumen.
Materials and methods
Cell culture and DNA constructs
Mouse embryonic fibroblasts were isolated from calreticulin-deficient and
wild-type embryos, immortalized, and designated K41 and K42, respec-
tively (Nakamura et al., 2000). K42 crt
 /  cells were transfected with the
pcDNA3 expression vector containing cDNA encoding rabbit calreticulin
to generate crt
 /  cell lines expressing recombinant calreticulin (desig-
nated K42CRT). K42 cells were also transfected with expression vectors
encoding the N   P domain or P   C
 domain of calreticulin to generated
K42N P and K42P C lines, respectively. cDNA encoding the N   P do-
main of calreticulin (amino acid residues 1–287) was synthesized by PCR-
driven reaction using the following oligodeoxynucleotides with 5  flanking
EcoR1 (primer N5 ) and Kpn1 (primer P3 ) restriction sites: N5 , 5 -ATAT-
GAATTCATGCTGCTCCCTGTGCCGCT-3   and P3 , 5 -ATATCTCGAG-
GTCGGGCGAGTACTCGGGGT-3 .
cDNA encoding the P   C domain of the protein (amino acid residues
172–401) was synthesized by PCR-driven reaction using the following P5 
and C3  primers with 5  flanking Kpn1 and Xho1, respectively: P5 , 5 -
ATATGGTGACCAACAGCCAGGTGGAGTCGGG-3   and  C3 , 5 -ATA-
TCTCGAGGCCGGCGGCCGCCTCCTCCT-3 .
cDNA for the N   P and P   C domain was preceded by cDNA encod-
ing calreticulin signal sequence and COOH-terminal KDEL ER retrieval
signal.
SDS-PAGE and Western blot analysis
Cells were lysed, and proteins were separated by SDS-PAGE (10% acryl-
amide) and transferred to nitrocellulose membrane (Mery et al., 1996).
Blots were also probed with goat and rabbit anticalreticulin (Nakamura et
al., 2000), antibradykinin B2 receptor antibodies (Blaukat et al., 1996), or
rabbit anti-SERCA2 antibodies at a 1:1,000 dilution (Lytton et al., 1992).
To assess the level of InsP3R protein, microsomal membranes were iso-
lated from wild-type (K41) and crt
 /  (K42) cells (Lytton et al., 1992) and
from RBL-2H3 cells as control (Vanlingen et al., 1997). Membrane pro-
teins were separated on SDS-PAGE, transferred to Immobilon-P and
probed with isoform-specific antibodies against InsP3R type 1 (Rbt03, dilu-
tion 1:1,000), InsP3R type 2 (Rbt02, dilution 1:200), or InsP3R type 3
(I31220, dilution 1:2,000; Transduction Laboratories) (Parys et al., 1995;
De Smedt et al., 1997). Quantification of the immunoreactive bands was
performed after incubation with secondary antibodies coupled to alkaline
phosphatase detection using Vistra™ enhanced chemifluorescence and
fluorimaging as described before (Vanlingen et al., 1997). Statistical analy-
sis of the InsP3R isoforms levels in the K41 and K42 cells was performed
using the paired Student’s t test after normalization of the levels to those
found in microsomes of RBL-2H3 cells.
Reverse transcriptase PCR analysis of InsP3R mRNA
Relative levels of mRNA encoding different isoforms of InsP3R were deter-
mined by reverse transcriptase PCR (De Smedt et al., 1997). PCR products
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alized by staining with Vistra Green (followed by fluorimaging and quanti-
tative analysis on a Storm840 FluoroImager equipped with the Im-
ageQuaNT 4.2 software.) GAPDH mRNA was used as an internal
standard.
Total and free ER luminal Ca
2  concentrations
The total Ca
2  in ER Ca
2  stores was estimated using 
45Ca
2  (10  Ci/ml) as
described earlier (Mery et al., 1996). Free [Ca
2 ]ER was estimated by dual
emission ratio imaging using the ER-targeted yellow cameleon (YC4ER)
(Miyawaki et al., 1997; Arnaudeau et al., 2001). Cameleon fluorescence
was imaged at 37 C on a ZEISS Axiovert S100 TV equipped with 430   10
nm excitation and two emission filters alternated by a filterwheel. Images
were acquired on a 12-bit cooled CCD camera controlled by the Meta-
morph/Metafluor versus 3.5 software. [Ca
2 ] was calibrated from the YC4ER
fluorescence ratio R (535/475 nm) using the following equation:
[Ca
2 ]   K d[(R   (Rmin   14 / 100*(Rmax   Rmin))) / (Rmax   R)]
(1/n)
where Rmax   ratio obtained in the presence of 10  M ionomycin and 20
mM CaCl2, Rmin   ratio obtained in the presence of 10  M ionomycin and
20 mM EGTA, K d   292  M, the apparent dissociation constant, and n  
0.60, the Hill coefficient of the fitted Ca
2  calibration curve. This curve
was obtained in situ on mouse embryonic fibroblasts expressing YC4ER,
permeabilized with ionomycin (10  M) and digitonin (5  g/ml), and incu-
bated with different Ca
2 -containing solutions buffered with 5 mM EGTA
and 5 mM HEEDTA below 100  M free Ca
2  calculated according to Bers
et al. (1994).
Cytoplasmic Ca
2  measurements
For measurement of [Ca
2 ]c, cells (1.5   10
6/ml) were loaded with the flu-
orescent Ca
2  indicator fura-2/AM (2  M) (Mery et al., 1996). Cells were
stimulated with 200 nM bradykinin, 100  M carbachol, 1  M angiotensin
II, 50 nM bombesin, 10 mM caffeine, or 25 ng PDGF/ml of medium. For
direct addition of InsP3, cells were permeabilized with saponin (Favre et
al., 1994).
InsP3 level measurement
For InsP3 level measurements K41 and K42 (4   10
7 cells), cells were incu-
bated for 15 s with 200 nM bradykinin, and the reaction was terminated by
addition of an equal volume of 15% trichloroacetic acid. Acid-treated cells
were centrifuged at 3,000 g for 15 min at 4 C, extracted with water-satu-
rated diethyl ether, neutralized with NaHCO3 followed by the D-myo-
[
3H]InsP3–binding assay, which was carried out as recommended by the
manufacturer (Amersham Pharmacia Biotech).
Bradykinin binding
Cells were plated at 2   10
4 cells/ml in 24-well (1 ml/well) and equili-
brated on ice for 10 min with a binding buffer containing 20 mM Hepes,
pH 7.4, 17 mM NaCl, 5.4 mM KCl, 0.44 mM KH2PO4, 0.63 mM CaCl2,
0.21 mM MgSO4, 0.34 mM Na2HPO4, 110 mM N-methylglutamine, 0.1%
BSA, and 2 mM bacitracin. Cells were then incubated with different con-
centrations of [
3H]bradykinin (0.38–6.4 nM) in the presence or absence of
10 µM bradykinin. Cells were washed with a binding buffer, resuspended
at 250  l/well in ice-cold 100 mM NaOH and counted by scintillation
counting. Binding assays were performed for 4 h at 4 C in triplicate.
Immunostaining, fluorescence microscopy, and flow cytometry
Immunostaining and confocal microscopy were carried out as previously
described (Nakamura et al., 2000). Goat antibodies against calreticulin (di-
luted 1:50), rabbit antibodies against Grp94 (diluted 1:50), PDI (diluted 1:50),
and bradykinin receptor (diluted 1:100) were used. The secondary anti-
bodies were: FITC-conjugated donkey anti–goat IgG (H   L) (diluted 1:50)
and FITC-conjugated goat anti–rabbit IgG (H   L) (diluted 1:50).
For flow cytometry, fibroblasts were suspended in a solution containing
1 mM EDTA, 150 mM NaCl, 50 mM Tris, pH 7.3, washed, incubated with
PBS containing 2% FBS, and labeled with rabbit antibradykinin receptor
antibodies at a 1:10 dilution for 20 min at 4 C. Secondary antibody was
anti–rabbit FITC antibody at a 1:50 dilution. Analysis was carried out with
a Becton Dickinson FACScan using CellQuest software. Results are pre-
sented as the relative mean fluorescence intensity of the population la-
beled with primary and secondary antibodies minus that obtained with
secondary antibody alone. Results shown are representative of five experi-
ments.
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